Isolation and antifungal sensitivity to Candida isolates in young females

• Authors: Y. Adesiji , N. Ndukwe , B. Okanlawon
• Languages of publication: EN

Abstracts

EN

A survey of 104 sexually active young females tested on on cervico-vaginal swabs showed that 26 of the females (25%) had vulvovaginal candidiasis with a species distribution of Candida isolates accounting for 13 (50%) with C. albicans, 6 (23%) with C. glabrata, 1 (4%) with C. krusei, and 6 (23%) with C. tropicalis. Of the 26 (25 %) subjects that were positive for VVC, 8 (7.8 %) were symptomatic and 18 (18.8 %) were asymptomatic. However, distribution among different age groups revealed an increase in the 23–27 age group. The comparative analysis of sensitivity of the given fungi to the number of antimycotic preparations used revealed the following: in fluconazole, 2 (7.8%) isolates were sensitive, 5 (19.2%) were susceptible and dose dependent, and 19 (73%) were resistant. For voriconazole, 4 (18.4%) isolates were sensitive, 6 (23.1%) were susceptible and dose dependent, and 16 (61.5%) were resistant. For nystatin, 5 (19.2%) isolates were sensitive, 10 (38.5%) were susceptible and dose dependent, and 11 (42.3%) were resistant. It appears that Candida isolates have a variable resistance response, but 19 (73%) had maximum resistance of the isolated fungi of the genus Candida to fluconazole. Therefore, further studies on the evaluation of combination therapy should be considered for a better outcome in treatment of vulvovaginal candidiasis.

Keywords

EN

Candidiasis epidemiology; Young Female; Antifungal Sensitivity Tests; Nigeria

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2011
• Volume: 6
• Issue: 2
• Pages: 172-176

Dates

published

1 - 4 - 2011

online

17 - 2 - 2011

Contributors

author

Y. Adesiji

• Department of Medical Microbiology and Parasitology, PMB, 4400, Osogbo, Nigeria

author

N. Ndukwe

• Department of Biomedical Science, College of Health Sciences, Ladoke Akintola University of Technology, PMB, 4400, Osogbo, Nigeria

author

B. Okanlawon

• Department of Biomedical Science, College of Health Sciences, Ladoke Akintola University of Technology, PMB, 4400, Osogbo, Nigeria

References

• [1] Nwokedi E, Omole-Ohonsi A (2007): Current Clinical Review of Vulvovaginal Candidiasis (VVC). Journal of Medicine and Rehabilitation: 1: 28–32
• [2] Onifade AK, Olorunfemi OB (2005): Epidemiology of Vulvo-vaginal Candidiasis in Female Patients in Ondo State Government Hospitals. International Journal of Food, Agriculture and Environment: 3: 118–119
• [3] Sexually transmitted diseases treatment guidelines (2006): Centers for Disease Control and Prevention. MMWR Recomm. Rep. 55(RR-11): 1–95
• [4] Sobel J, Chaim W, Nagappan V, Leaman D (2003): Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. Am J Obstet Gynecol 189: 1:297–300 http://dx.doi.org/10.1067/S0002-9378(03)00726-9[Crossref]
• [5] Sobel JD (1998): Vulvovaginitis due to Candida glabrata. An emerging problem. Mycoses 41(suppl. 2): 18–22 http://dx.doi.org/10.1111/j.1439-0507.1998.tb00594.x[Crossref]
• [6] Gygax S.E, Vermitsky JP, Chadwick SG, JS Matthew, J A. Zimmerman, E Mordechai, M E. Adelson, 3 and J P. Trama: Antifungal Resistance of Candida glabrata, Vaginal Isolates, and Development of a Quantitative Reverse Transcription-PCR-Based Azole Susceptibility Assay Antimicrobial Agents and Chemotherapy, 2008: 52(9): 3424–3426 [WoS]
• [7] Ribeiro M, Dietze R, Paula C, Da-Matta D, Colombo A (2000): Susceptibility profile of vaginal yeast isolates from Brazil. Mycopathologia 15: 5–10
• [8] Arthington-Skaggs B, Motley M, Warnocks D, Morrison C (2000): Comparative Evaluation of PASCO and National Committee for Clinical Laboratory Standards M-27-A Broth Microdilution Methods for Antifungal Drug Susceptibility Testing of Yeast. J. Clin. Microbiol. 38: 2254–2260.
• [9] Clinical Laboratory Standards Institute (2007): Reference Method for Disc diffusion Antifungal Susceptibility of yeasts Approved standard M-44-A. CLSI, Villanova, PA, USA
• [10] Howard L (1991): Epidemiology of Vagintis. American journal of Obstetrics and Gynaecology, 165: 1168–1176
• [11] Enweani IB, Ogbonna CI, Kozak W (1987): The incidence of candidiasis amongst the asymptomatic female students of the University of Jos, Nigeria. Mycopathologia. 99: 123–141 http://dx.doi.org/10.1007/BF00437435[Crossref]
• [12] Ako-Nai AK, Kassim OO, Adeniram MO, Taiwo O (1993): A study of urinary tract infections at Ile lfe, Nigeria. East African Med J. 70: 19–14
• [13] Vermitsky JP, J Matthew. G. S. Sean. J. P. Chadwick. M. E Trama, A, E Mordechai and S.E. Gygax (2009): A Survey of Vaginal-flora Candida species of Different Age Groups Using species-specific PCR Detection. J. Clin. Microbiol. doi:10.1128/JCM.02485-07 [Crossref]
• [14] Watson C and Calabretto H (2007): Comprehensive review of conventional and non-conventional methods of management of recurrent vulvovaginal candidiasis. Austr. J Obstet Gynecol. 47: 262–272 http://dx.doi.org/10.1111/j.1479-828X.2007.00736.x[Crossref]
• [15] Solanki A, Mathur D, Joshi K (1983): Bacterial, fungal and parasitic flora in vaginitis. J Indian Med Assoc 1983; 81: 151–153
• [16] Holland J, Young M, Lee O, Chen S (2003): Vulvovaginal carriage of yeasts other than Candida albicans. Sex Transm Infect 2003; 79: 249–250 http://dx.doi.org/10.1136/sti.79.3.249[Crossref]
• [17] McCormack WM, Starko KM, Zinne SH (1998): Symptoms associated with vaginal colonization with yeast. Am. J. Obstet. Gynecol. 158: 31–33
• [18] Enweani IB, Gugnani H, Okobia R, Roseline Okobia, Ojo SB (2001). Effects of contraceptives on the prevalence of vaginal colonization with Candida species in Edo State. Microbiol 18: 171–173
• [19] Kikani BA, Kikani KM, Pathak SJ (2008): Effects of chemically synthesized azole compounds on clinical isolates of Vaginal Candidiasis, in comparison with commercially available drugs. The internet journal of Microbiology. 4–2
• [20] Okungbowa FI, Isikhumhen SO, Dede PO (2003): The distribution frequency of Candida species in the genitourinary tract among symptomatic individuals in Nigerian Cities. Micrologia 20: 60–63
• [21] Koutsoukou A, Stylianakis A, Tsiplakou S, Tachtatzis M., Tsakona E., Vourtsi A., Sideri A (2005): A 3-year study of resistance of candida pathogens obtained from patients with fungemia with emphasis to new antifungal agents. Athens Med J. p 1228
• [22] Cruz O, (2003): Species distribution and antifungal susceptibility profile of Candida spp. Bloodstream isolates from Latin American Hospitals. J. Clin. Microbiol; 98: 401–5
• [23] Ferris D, Nyorjesy P, Sobel J, Soper D, Pavletio A, Litaker M (2002): Over the counter antifungal drug misuse associated with patient diagnosed vulvovaginal candidiasis. Obstet Gynecool: 99: 419–425 http://dx.doi.org/10.1016/S0029-7844(01)01759-8[Crossref]

Identifiers

DOI

10.2478/s11536-010-0071-0